Research, development, production, and marketing of prescription medicines in five therapeutic areas: cardiovascular, renal & metabolism, oncology, respiratory & immunology, rare diseases, and vaccines and immune therapies.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
AstraZeneca
B
Research and development of pharmaceuticals and biotechnologies for various diseases, including cardiovascular, renal, and metabolic diseases.
Chiesi SAS
B
Development and marketing of pharmaceuticals in respiratory, neonatology, transplantation, and rare diseases.
GlaxoSmithKline France
A
Research and development of pharmaceuticals in respiratory, immunological, inflammatory diseases, oncology, HIV, and infectious diseases.
Initiatives identified among leaders
Réduction des émissions de gaz à effet de serre
“GlaxoSmithKline France a pour objectif de réduire ...” - GlaxoSmithKline FranceSuivi des émissions et consommation énergétique des sites
“AstraZeneca mesure et publie des indicateurs envir...” - AstraZenecaRéduction des émissions de carbone et protection de la nature
“GlaxoSmithKline France prend des mesures pour rédu...” - GlaxoSmithKline France64% of similar organizations communicate on CSR issues
+1463 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports